Work

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis

Year: 2013

Type: article

Abstract: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA patients (pts) when dosed every other week (eow) for up to 3 years [ 1 ], but the effect of ADA on growth is not known.

Source: Pediatric Rheumatology

DOI: 10.1186/1546-0096-11-s2-o4

Authors: N Ruperto, DJ Lovell, K Jarosova, D Nemcova, V Vargová, H Michels, EC Chalom, N Ilowite, C Wouters, HI Brunner, KK Kracht, H Kupper, E Giannini, A Martini, N Mozaffarian

Institutions: Cincinnati Children's Hospital Medical Center, AbbVie (United States), AbbVie (Germany)

Language: English

Topic: Autoimmune and Inflammatory Disorders Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,090

OpenAlex ID: W2109959693

FWCI: 0.238

Cites: 1

Cited by: 2

Related to: 10